3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Active not recruiting
6
Terminated
3
Withdrawn
2
Unknown
2
Recruiting
2
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Chordoma
1
Interventions
Paclitaxel
28
Trastuzumab
22
Cyclophosphamide
21
Doxorubicin
14
Docetaxel
14
Carboplatin
11
exemestane
10
Radiotherapy
10
Letrozole
10
Capecitabine
10
pembrolizumab
8
Lapatinib
8
Fulvestrant
8
Neoadjuvant Therapy
6
Goserelin
6
Bevacizumab
6
Anastrozole
6
pertuzumab
5
palbociclib
5
eribulin
5
abemaciclib
5
Therapeutics
5
Magnetic Resonance Spectroscopy
5
Epirubicin
5
Chemotherapy, Adjuvant
5
Aromatase Inhibitors
5
tucatinib
4
Vinorelbine
4
Taxes
4
Tamoxifen
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Breast Neoplasms
×
avelumab
×
Clear all
NCT04188119
2025-12-08
IMpALA
The Christie NHS Foundation Trust
Phase 2
Withdrawn
NCT03794596
2019-07-22
IMpALA
The Christie NHS Foundation Trust
Phase 2
Withdrawn